|
|
|
- しょうこ てっちがわら
- 7 years ago
- Views:
Transcription
1 2004 ( ) P.5 P.11 P.20 P.27 P.31 P.47 P.53 P.61 P.67 P.77 P.80 P.83 P.86 P.97 P.101 P.111 P.113 P.117 P.116 P.119 P.119 P.127 P.132 P.133 K P.134 K P.135 Na P.137 Na P.139 Ca P.141 P.145 P.151 P.152 P.156 P.161 P.169 P.173 P.179 P.184 P.188 P.187 P.190 P.193 / P.194 P.197 P.199 P.198 P.201 P.205
2 DC
3 / BUN/CRE K K Na Na Ca Ca /
4 / / /
5 / Xp/ Y / / Y Y / / Xp Y / COPD Churg-Strauss / BUN/CRE/BNP ANCA/ /IgE/
6 / / 2l SpO290 a a COPD CO2 SpO2 COPD
7 CO2 CO2 HCO3 COPD SpO2< ml+ 5ml 20 2 COPD
8 8 1 a BUN/CRE WBC/CRP GOT/LDH/CK / a 2 ( P.77 ) 200mg a a % *1 *1
9 1.1 9 : * ml+ 5ml * ml+ 5ml ml+ 10ml mg *4 0.3ml CO2 CO2 SpO2 90 *5 1 *2 * *4 *5
10 10 1 *6 *7 p.51 ACE NSAIDs IgE (40-80mg ) 2 200mg/1X Churg-Strauss ( ) P-ANCA 40-80mg/ *6 *7
11 mg/kg/ P.77 β 1.2 Xp /Xp/ Y Y Xp Y N Y CT BNP CO COPD / BNP D-dimer IVC Xp/CT D-dimer
12 % 31% COPD 9% 7% 5% 4% 2% 2% l / /
13 /DKA CO2 COPD / / / a / b LDH a b a / a
14 14 1 a 200mg b 0.5ml+ 5ml a b 4 200mg CTR / / /PaO 2 / /
15 SPO2 * P.8 3 COPD P.20 / / Xp CT COPD 15% / / 50% *8 SPO2
16 16 1 SpO2 CT( HRCT) SpO2 80 LDH KL-6 ESR ( ) 1000mg mg/1X 1000mg 500mg 200mg *9 1-2mg/kg/ SpO2 10l SpO2 90 (DVT) / ICU *9
17 SIQIIITIII *10 T *11 CT *12 D-dimer * ml 5ml/h 3. APTT *14 / * 15 / / mg/dl 600mg/dl. ph ph> mg/dl 360mOsm/l *10 *11 *12 60% 80-97% *13 97% 45% *14 *15
18 18 1 (p.148 ) ml/ ml ml 3. 1/ U/kg/h * mg/dl 1-2U/h 4. 1U /h 5. ph 7.0 ph 7.2 HCO 3 = 0.25 (Kg) ( base excess : BE) P.77 / BNP *17 *18 *16 *17 / *18 BNP
19 ACE * mg K BUN/CRE β / 15 / / * *21 2. / 100mg 3. 1g+ 100ml 4. *22 IVH *23 * 24 P.156 * mg *20 *21 *22 3 VCM *23 VCM+ *24
20 20 1 p.24 / CO2 1.3 = Na + (Cl + HCO 3 ) Y Y Y HCO 3 24 BE 0 ph 7.4 Y CO2 Cl CO2 Gap 20mEq/L Non-Gap HCO 3 Y COPD / NSAIDs AaDO2 NaCl/KCl K/ Mg COPD 9% Xp FEV % 70%
21 CO2 room air HCO3 29meq/L CO2 Y A ado2 = PaCO2/0.8 PaO2 30 COPD Xp CT Y / ALS CT/MRI / *25 COPD COPD Xp HCO 3 COPD SpO2 90 2l *25 DL CO 60% 50%
22 22 1 ph PaCO2 PaO2 1. PaCO2 1mmHg ph *26 2. PaO2 PaCO2 room air 140 PaO2 3. ph 7.25 PCO2 90mmHg PO2 35mmHg BE 5mmol/l 4. ph CO mmHg PaCO2 70mmHg PO2 PCO PaO2 70mmHg ph 7.40 PCO2 70mmHg PO2 70mmHg 6. CO2 0.5ml+ 5ml 2 200mg a a 4 200mg *26
23 COPD / COPD O2 /CO2 Xp IPAP 4cmH2O EPAP 8cmH2O *27 *28 *27 200mg/2X *28 2 3T/3X-4T/2X
24 24 1 *29 A-aDO2 COPD *30 CO2 / / 1 ( p.189) ( p.188) ( ) *29 *30
25 Na K HCO3 Y Y 12 Y Y AG = Na + (Cl + HCO 3 ) / 200 BUN/CRE/ ph7.2 / B1 Y ph >5.5 I ph 5.5 II IV I II IV 20mEq/l 3-6g/3X
26 T/3X P.148 ph 6 * ( ) glu ( BUN ) 2(Na + + K + ) B ml/h *32 * *31 BUN * mg *33 1
27 *34 ( ) 50mg 100mg glu LDH TP ph LDH LDH 6 LDH 6 5 Y ph ph 6.0 ph ph 7.0 Churg-Strauss SLE CT GIF *34
28 28 1 IFN-γ (140pg/ml ) 10-27% 3% 2% 30-48% 11-17% 15-20% 3-6% 0.3% 5% / ph7.00 glu 40 LDH
29 * ml 2 3 Xp Xp ADA IFN-γ 60% *36 1% 20ml NSAIDs 1 20mg KE 500mg 50ml 4-5g 50ml *35 *36
30 30 1 P.18 P g/ *37 P.114 5% ph * mg/1X 25mg/1X
31 ph Xp / / Y PT/APTT/ Y / Y Y / / / CT / CT ANCA HRCT 25mg *38 *38
32 32 1 COPD 2-3 Xp CT 200mg/1X 24 P.209 H2 Wegener ( P.44) MPA Churg-Strauss ( P.10) P-ANCA/C-ANCA
33 P ( 1.1) 1.1 ( 1.2) 1.2
34 = 1.4
35 =
36 ( 1.6) 1.6 CPR ( 1.7) 1.7 ( 1.8)
37 ( 1.10) ( 1.11)
38
39 % 22cm 5cm
40 cm 10cm CO2 CO2 CO2 *39 ( 1.14) *39 CPR ETCO2 CPR
41 *40 *40 Resuscitation 56 (2003) The assessment of three methods to verify tracheal tube placement in the emergency setting Department of Emergency and Critical Care Fukuoka University School of Medicine
42 *41 Xp a a 15 3A+ 85ml 5ml/h 1A+ 20ml 0.5ml a a *41
43 / ARDS CT PaO2/FiO2 200
44 44 1 Y Y 3cm Septic Embolism Wegener 7-10cmH2O PEEP 30cmH2O 1 *42 CO2 20 Wegener C-ANCA 90% X CT *42 50kg ml
45 mg/kg 1mg/kg 1 5% ACE *43 CD4/CD8 *44 30mg/ / Xp *45 X * % *44 2/3 * %
46 46 1 CRP T CD4/CD mg/ Xp 2 2mg/kg 7-15mg/kg * 46 *46 Goodpasture
47 Y Y / CVP ( ) / Xp / CT / N / / Y / 200mg
48 a a / 500ml a a 3A+ 85ml 5ml/h 1A+ 20ml 0.5ml
49 / / / γ 1γ = 1µg/kg/min γ 7γ 0.07γ γ *1 *1
50 50 2 γ γ 3 3A+ 85ml a 1ml/h 50kg 1γ 5-7γ 15γ a D:600mg/200ml 3A+ 85ml 1ml/h 50kg 1γ 1A a + 19ml 0.5-1ml a 1A 1mg/1ml 3A+ 97ml 1ml/h 50kg 0.01γ γ *2 1A+ 20ml 1ml/h *2 5-10ml/h
51 mmHg P.16 PCPS 0.02% β 6% /
52 ml * mg *4 5mg P25-50mg H2 *5 P.56 MI P.15 Xp 2-3 / P.100 P mg 1 /h C *3 *4 *5 H1 H2
53 / Xp / Y Xp Y - 12 / Xp/ Xp CT CT 5000 CAG 120mmHg ( 2.1) / / Xp SpO2
54 % 24% 9% 5.8% 5.8% 5.4% 5.0% l / /
55 CAG a a BUN/CRE CAG CK/CK-MB/GOT/LDH -i a / b CRP / a b 12 ST ST / 200 1/2A a CAG a
56 56 2 / a a a / a CT / 1/4 12 ST ( 2.1)
57 CK/CK-MB 4 20 WBC LDH GOT 2.1 A F *6 100ml/h *7 PTCA mg ACE *8 *9 * *7 PTCA IABP *8 *9
58 58 2 ST CT mmHg *10 β *11 2-3ml/h (2mg) 1/2A mg+5%glu90ml 3ml/h 18ml/h 100mg(2A)+5%glu100ml 5ml/h 15ml/h *12 *13 CT *10 dp/dt *11 *12 15mg *13
59 D-dimer SpO / 3 APTT APTT mg/1X PT PT-INR 2-3 CT 20% ST R ST *14 *14 reciprocal change
60 60 2 NSAIDs NSAIDs P.64
61 Y 12 Y Y CT / SSS QT ( ) HOCM Holter CT / AS/MS CAG Holter CK/ /CAG EPS / CK /
62 % 3% 3% 2% 2% TIA 2% 15% 10% 2% / / /12 QT ST LVH AS/
63 CK / K Ca Mg / / MS/AS/HOCM a a CT a CT a
64 / β 2 60mmHg ACE
65 cm QRS 3 5 MobitzII 2.3 MobitzII PQ QRS QT 2.4 QT
66 66 2 ST QT PVC QT *15 Mg Burugada 2.5 Burugada 3 coved saddle-back ICD 2.5 V1 p % P CK *15
67 / DC 200J Y Y Y Y QRS 3 RS RS 100msec Y P RP PR AVNRT AVRT ATP 10mg 12 f 5mg β / / β / a a
68 QRS QRS QRS QRS QRS WPW QRS 1A 2 10 QRS 2% 1/2A(50mg) 1 5 a a
69 QRS Y 12 P P QRS P QRS P N PQRS Y Y QRS II III avf AVRT AVNRT WPW β β QRS 2.6 ( )QRS QRS P
70 Y Y Y 12 ST Y / P QRS Ca
71 QRS P QRS AVRT AVNRT 10mg / 3 * mg 1 5mg(1/2A) mg/kg 2 15 *16
72 QRS % % 5% 2T/2X-3T/3X mg mg1 2 40mg mg mg1 1 ( ) /
73 β QRS QRS DC 12 RR RR Y QRS QRS Y QRS QRS β PVC WPW Y RS RS 100msec / / WPW Mg QT /
74 *17 QRS *18 Lown ( ) 1 : : : (2 QRS ) 4A :2 4B :3 ( 2.11) 5 :R on T(VPC QRS T ) I *19 *17 *18 coupling interval *19
75 QRS Na K Cl Ca Mg 12 QT DC VT/Vf VT 30 VT( 2.12) ( ) Vf (RR ) *20 *20
76 RS a a RS 100msec *21 ( ) 1. 50mg mg mg 1000mg J Vf *22 *21 vf *22
77 Xp Y Y SAH /Xp ARDS CT BNP CT BUN/CRE /
78 78 2 SpO2 90 CPAP CO2 / ph7.2 SpO2 90 ST
79 / GOT/LDH/CK LDH BUN/CRE 1A(20mg) 120 3mg a 3 SpO2 96% 30% a 1/2A 120 3A+ 85ml 3ml/h ml 1ml/h 80 ACE *23 25mg/1X * mg/1X 25mg/1X
80 80 2 *24 CPAP BiPAP 5-7cmH 2 O PEEP 2.6 BUN/CRE BNP Y IVC BNP Y SVC N Xp CT NSADIDs Ca CT BUN/CRE CT CT g mg/dl *24
81 BUN/CRE/ 40% IgA 10% 6% SLE / 1 *25 3-5g/ 2g/dL ACE *26 BUN/CRE P mg *27 Kussmaul *25 *26 2.5mg/1X *27
82 82 2 CT dip and plateau /ACE P.114 non-pitting edema CK F-T 3 F-T 4 TSH TSH
83 / / / CT / Y Y K 3.5mEq/L 1 14µg/ Y Y N NSAIDs MAO / Y MIBG Ca 70% 10% 6.7% 10% 3.3% 0.6% 2.3
84 m ng/ml/h 150% % ( ) µg/kg/min ( ) 5-15mg/h 5-100µg/min/ 25mg *28 2 NSAID MAO *
85 ASO 15-25% / / CT ACE PTA 24 ( 15µg ) ( 120µg ) ( 700µg ) MIBG / β α
86 86 2 K CT/MRI Ca ( ) 2.8 CPR ( 2.13) 2.13
87 2.9 DC cm ( 2.14) DC DC * 29 Vf 90% % 4 3 *30 *29 *30 Effects of Cardiopulmonary Resuscitation on Predictors of Ventricular Fibrillation Defibrillation Success During Out-of-Hospital Cardiac Arrest Circulation : 10-15
88 J kg
89 ; J 360J ;2 4 4J/kg 4J/kg 2 (QRS ) R on T VT VF 2.10 CPR ( ) or CPR
90 90 2 PEA a a Vf 200J 300J 360J 3 360J a a
91 CTR / Vf 1A 5 PEA/ 1A 2A a 5 a 3 6A K
92 92 2 a Vf 2% 1/2A 2 (3 ) Mg1A 10% a PEA/ a a Vf ACLS2000 K HCO 3 HCO 3 = 0.25 (Kg) ( base excess : BE) Vf * 31 *31 ACLS 10
93 gg ÁÁ ÁÁ gg gg gg gg ÏÏÏ ÏÏÏ v gg gg gg ƒ ÁÁÁ ÁÁÁ ACLS 2000 CPR CPR. / <-%Y a 0 Ç21 È È 23 ËË ;: < =.t< &8 M8 M8 8!`a üvýî!`a Ü " á â Ü " á*â {{ #(! $Œ<%+&'%+ (M %+ *,+-% #(! $Œ<%+&'%+)(M %+ *,+-% Ü "$.< ÜÝb Þß àœ TT *á âb+bãm< T T ä ä.yåjæçvè é/ê"ëì Ç í/îmïñð [òvó ô õö$ / Jæç*ø$ùú [ û üvýî þÿ õö$ / Jæç*ø$ùú [ û üvýî þÿ 6>A@ Ï c ÐÑ ÒÒÒÒ 8JÓÕÔ ÆÆÆÆ Ï cö$ "Ø ÙÙÙÙ 8ÚÛ cde$f*g ghcdij cd e$f g ghc dijyk"l ÀÀÀÀÀÀÀÀ ef e$f 88wÁ Á  Â ÃVÄÅÆ cdef g ghcdijyk"l ÇÇ ˆÈ$ÉÊ T$Ë ÌÌ ÍÎÉ c ÐÑ cðñ ÒÒÒÒÒÒÒÒ $b $"!$#&%('*) +*,*-/."012&%43$ 5*6$7M8J:;=<>+ A@CBEDGFHJI KLMONP 5*6$798(:;=<>+ A@CBEDGFHJI KLMONP QRS"T L/+VU WLXY+*Z [9\$HV]$^_`ba cðñ$ò cdef g ghcdij cdijbk"l k"lnm Áƒ *à oqp rsou oqp*rtsou p rsouwvyx z {}vyx z~ vy p*rtsouwvyx z {}vyx z~ vy (ƒh - ˆ cdef g ghcdij cdijnm o Š= V Ž u o ŠŒ " Ž u Š= V Ž um ŠŒ " Ž um CŽ Vu CŽ Vu> *žÿ {š hv œ o 9 O 9 u o 9 u 9 O 9 u vyx z 9 u vyx z ˆ Y+ ƒh - b v œ {}Š= V Ž u {}ŠŒ " Ž u Š= V Ž uª Yœ ŠŒ " Ž uª Yœ NP «$.Y Y%* V 9 >u±vyx z 9 9 >u±vyx z ˆ /+ ƒh - ²$³ $µ µ m /¹Oº/» "¼ ½ %C¾ BDCEBGFIHIJGKMLONQPRFISQTIURVQWQXRYIWQZ\[^]`_acbd_^egfihjhkhmlOnIoRprqtsvuxwzy{} d~ 2.16
94 ýýýýýý YYY Z Z Z ff ff ýýýýýý.... X Õ Ü Ý W 94 2 Q QPª7Ÿ^«±M²5³ ±²@³ H µ $ $¹ H µ $ $¹ º»^¼¹ ½ º»^¼¹½ ± ± ± ± ± Q¾ ³ ³ ³ ³ ³ ³ ³ ³ &%('*),+ -M... :$< S B'DCE+ F Gz%JIöKM. B'DCE+ F Gz% ILKM..HÀ Á oq: 0%('wv xzy + Fz%{ }I7. 0%('wv xzy +LF0%{ }I7..ÃÂ2Ä^ÁQÅQ Æ2Ç ÈpÉ e@ê ËCE z% ËB'Ã%Ey y + F0%{ }I7. ËCE z% ËB'Ã% yey + F0%{ }I7..Ì Í «OÎ,Ï «^ÎBÏ Ð Í$ÑÒ u57suó 3OÔÖÕL E }Ø,Ù ÕL E ÛÚ Ü }ØBÙ Ü ÝL }Ø pþqß@ àâá Üäãå / Ÿ^«$A Ÿ^«QA 33 UUÕLæÐ RŸ «` \ Œ 3MçQèéê ë Rì íîï eñð;ò î Rì íîï eñð;òî / Üäã^óõô7Ô bb Y[Z»^¼¹\ ]^_`/a$bdc ]e$¼¹f fhg gggggg 0i ] ej k$lmnpoq b "/r "!$# &%('*),+ -..0/ ;: <$=>@A ;: <$=>@A 33 B'DCE+ F GH%JILKM... =>ONQPROST UWVX$Y Z[\R^]_ `ab UWVX Y B'DCE+ F GH%JILKM... :$<cdegf7r[\ `a5h :$<cdegf7r[\ `Qa@h 3iOj B'DCE+ F GH%JILKM..lk$mQn po:$qrstu57st po:$qrstou@7st 0%('wv xzy{+ F0%{ }I7.. ~OQ.l~O S 0%('wv xzy{+ F0%{ }I7.. ƒq.l ƒ O ˆ e O ˆ e 0%('wv xzy{+ F0%{ }I7.. ƒq.l ƒ Š 2ŒO ŽQ 2 ^ Q Š 2Œ^ ^ŽQ 2 ^ Q z% E ECB'wC ILF0% +zỹ z%{+ K}IL } H%J 7. Ḧ% + K}IL } H%J 7.. š.lš t^œ RO]ž Ÿ ø@ù ú û ü ý *þ ÿ ~ Ù ÜäÚ! QA å ýý NN ãã 54 ~»^¼¹ "$# Ü &%}ÝL '$() Ÿ^«Mu 4 Ÿ^«@ u 4 3Ô Ü ÝL }Ø UU å*æqð2/ê ë R +bg ãqù, -/.0/1 ± ± ± ± ³ ³ ³ ³ ý ± 2/3 ± ± ³ ³ ³ ³ 46587:9; ý CBDöb üegfihqý U=<> JA KQS jj bb L M úúúúúúúú /NPO U=Q R ÿ!s ÿ!s Œ TBDLb ;;;;;;;; FIHQý 465 EEEEEEEE UV<> UK$S U=<> UK$S jù /A A CBDLb»^¼¹ "$# 2.17
95 ÍÍÍ BB ÍÍÍ BB ÍÍÍ BB ÍÍÍ BB ÍÍÍ BB ÓÓÓÓÓÓ ÍÍÍ ÍÍÍ ÍÍÍ ÍÍÍ ÍÍÍ.... YY YY YY YY YY ÿ % k ø ý ,.-0/12!3 Ó wfxh BFxyB 5ÙxyB u D ' %{u +Fx Kˆ c :!;9 tno<=> Ó wùxh BFxyB 5ÙxyB u D ' %{u+ùx u D0%760%UD Kˆ c :!;9 t O<=> 33 p A@02 a ¼ ¼ ¼ ¼ ¼ ¼ ¼ ¼ ½¾ KÀNÁNMí7 QÃÄ ¹ ½¾ KÀNÁ MÂ7 QÃÄ ÅÇÆ ÈÊÉËÊÌ ÍkÎÏNÐ ÈÑÒKÓ ÍÇÔQÕKÓ ÖeÉ &%('º),+J-. &%('º) : < PN A'CB + D EF%HGJI. A'CB +JDEF%HGJI..ÙØÚ nk: 0%('»uwÙxy+ D0%{z G7. 0%('»u wfxy+ D0%{z G7..eÛ2ÜÚNÝ Þ5ß!à á cêâ B F%yã,' % x xy+ D0%{zG7. B F%{ãA' % x xy+ D0%{zG7..k ä ÃKÄåAæ çn ä èké çn ä èé t šœot57ptê ëíì àî àî ïfð7 eœ ïêð7 eœ ¹a7!! #" $ &%('º) + -. &%('*),+ -..0/ ;: < =>5@ 33 A'CB +JDEF%HGJI. A'CB + DEF%HGJI... =K>LNMOQPR SUTNV W!XYNZO[\ ]N^ _ SUTNV W!XYNZO[\]K^ _ A'CB +JDEF%HGJI. A'CB + DEF%HGJI... : <aàbcedoykz]k^fg 3hi A'CB +JDEF%HGJI. A'CB + DEF%HGJI..kj lkmonk:npqrstf7pkr 0%('»u wfxy+ D0%{z G7. 0%('vuwFxy+ D0%{z G7..~}K PN 0%('»u wfxy+ D0%{z G7. 0%('vuwFxy+ D0%{z G7..~ ƒk Nˆ c 0%('»u wfxy+ D0%{z G7. 0%('vuwFxy+ D0%{z G7..~ ƒk ŠaŒa ŽQ N a Q e ŠaŒa ŽQ N a Q e N 0%('»u wfxy+ D0%{z G7. 0%('vuwFxy+ D0%{z G7.. N pf 33 t šœ tfž Ÿ S S ª,«J JC_ Jª,«J JC_ F%y BA'CBGJD0%y+Fx; F%y+ I GJz %H 7. F%y BA'CBGJD0%y+Fx; F%y+ I GJz %H 7..~±2² OQ[a³e O[a³e µ 2s ±2² OK acbd0efhg Ñij ÍCB B D &E CFy ùhgji ÍY Y I&Z Fy WX 9S MLC ú _ ÍCB B D &K G7I ÍY Y I ù N I #[ R I L» GJIQR ÍCB B D ML» ú N G ONQP IQRCG G ÍY Y N G ON N ù &X S ML I K ÍCB B D *L åos D JªUTWV ÍY Y S*L» ùuz G U[ R ML» ON I L D S]\O^&_ _ ÍCB B D &X S *L ùhgji ÍY Y S*L» ùuz G U[ CF ù ON I L D SU ù#z `F G ù _ ñêò óeôfõ ö øºù ú } ûaü ýaþ ÿ þ ÿ N@ f/ òö òö øºù ú } û ýý þ ÿ K@! N@! *"+ #"$&% ù ú å#' ú)( // 2.18 PEA / /
96 : i 96 2 ÁœF- œfedz1x{b % LªO«N R L H %±³² ³µ k O %±¹ º» k O %±¹ º%» ½¼R¾L»% e² OÀ À '&)(+*Á,F-/... : <%QO A(CBD, EDGH&JIFK/..žÂ%Ã.žÂ à nl: 1&)(vuwžxy, E1&{z I..eÄ3ÅÃOÆ }%Ç6È!ÉËÊ.eÄ3ÅÃOÆ }%Ç3È!ÉËÊ c³ì Dz Ï šh&í(+îr.. Ï6Ð ÑOÒ Ó3ÔÕ Ï6Ð Ñ Ò Ó3ÔÕ µ6ö ¹RØÙ µ6ö ¹ ØÙ DBDšž&yÚA(Û&DxDxy, E1&Vz I..k}%Ü ÝAÞ LßL} Ü àoá tãâäot6qtå tãâäëtfqtå æèç É/é %ê eä ëlì9í ØLÙOîfµ6Ö ØLÙOîfµ6Ö%..~} ï ðñ..... òoó ô ll p tèõ TVö Fø ù%úüûvýþaûdÿ f fâ `` /!! #"%$ '&)(+*, -/ ;: < =>6/@ 44 A(CBD,FEGH&JIFK/... =L> MONPRQS TVUOW X!YZL[LP\]%^O_%` TVUOW X!YZO[P\]%^O_%` A(CBD,FEGH&JIFK/... :%<abcedp ZL[ ^L_fg 4h i 4 h i A(CBD,FEGH&JIFK/..kj%lLmonL:Op qrs tfqs.kj%llmonl:op qrs tfqls 1&)(vuDwHxy, E1&{z I..~}O% ƒpqs 1&)(vuDwHxy, E1&{z I..~ L QO 1&)(vuDwHxy, E1&{z I..~} Lˆ Š OŒ c 1&)(vuDwHxy, E1&{z I..~} Lˆ Ž R O 3 e Ž R O R e H&yšDš BA(CBIFE1&y,Hx H&y, K IFz œž&yœ. H&yšDš BA(CBIFE1&y,Hx H&y, K IFz œ &Jœ.~Ÿ3 PR\ eƒ 3s Ÿ3 PL ;;;; ;;;; A B C D FE 44 ã 7 G6 7 G6 ' "!$#&%O@ (*)+, - ' "!$#&%O@. / Ý76 Ý ÁœF- œfedz1xyb ¹1H I JLK ¹,MLNLO,P>Q RRRR RRRR ÓÓÓÓÓÓÓÓ S S ðñlt ää 8 8 8ƒ LU 44 P t SWV X Y Y so,z [,\ ] ] T T t õ t õ S S ðñ P_^ a` bl@ 4Lc>dfe 4LcLdfe g g c hlp 4 t õ 2.19 DNR
97 / 10ml Y 10mmHg 10 Y Y Y / Mallory Weiss / GIF / GIF 10ml
98 % 24% 21% 10% Mallory-Weiss 7.2% 6.3% 2.9% / 95mmHg 30 a a 20G
99 CBC PT/APTT BUN PT/APTT / 2000ml SpO2 Mallory-Weiss GIF
100 % *1 NSAID 60% 1/3 *2 H2 (20mg) 1 20mg 1 2 (20mg) 1 20mg 1 2 *3 H. pylori 90-95% 4 (30mg)2C/2X (250mg)6C/2X (200mg)2T/2X 1. *1 GIF 25% *2 *3 50µg 25-50µg/h
101 PT-INR 2 FFP 20ml/kg 6 10ml/kg 3. 50µg 25-50µg/h 0.2U/min S-B tube / Y / Y Y / CT / CT( ) CT
102 102 3 Y / / CT / Ca Y / / Ca 3.2.1
103 / / / / / / Ca
104 ml 2 a a AMY CRP GOT/LDH AMY CRP WBC GOT/GPT/LDH/ALP / DM / φ3cm
105 CT / CT / a / a CT *4 30% 50mm *4
106 106 3 / *5 *6 3-4 Xp CT *7 *5 *6 *7
107 H2 PPI NG / / Charcot 3 GOT GPT LDH ALP bil *8 1A 20mg *9 - ERCP LDH GOT Ca 48 2 / 100ml/h *8 30% *9 PIPC/TZ AM/SB( )
108 mg/ mg/24 * g 1 2 *11 CT *12 *10 *11 *12
109 *13 *14 3cm NG *15 100ml/h 3P/3X *13 *14 / *15 1mm 3000ml
110 α *16 / NSAIDs / *17 P.111 *16 10% *17 25mg
111 Y 10mmHg 10 CBC S S - GIF 4-6 / 24 CF CF ml/
112 112 3 CF P-ANCA UC
113 LDH AMY glu alb alb - alb Y - alb 1.1g/dl Y / / N CT SBP / LDH LDH 0.6 CEA /
114 114 3 GOT 2 VitB1 * 18 30mg/ / PT/APTT DNA FFP VitK 10mg/1X 1L 10g *18 100mg/
115 TIPS SBP 20-30% / / 1g/dL 250/µL *19 2g g/kg 3 1g/kg ST / p.82 *19 1/3
116 Y Y Y ( K ) Y Ca/K N K CF Mg *20 2 *21 17g * ml/ 3 *21
117 *22 5-HT4 5 * 23 2mg % Y Y 2 Y CD Y N 40 IBS Y CD NSAIDs CF *22 *23
118 118 3 B 3g/3X 3g/3X *24 / CD 250mg mg * g1 4 *26 P.112 *24 *25 *26
119 Y Y Y NSAIDs 3.8 GOT GPT ALP γ-gtp bil Y ALP bil GOT/GPT Y γ-gtp ALP GOT / GPT
120 120 3 ALP bil γ-gtp Y Y Y γ-gtp ALP 2 ERCP/MRCP Y ALP CT N or PBC/PSC ERCP/ PBC M2 (CNSDC) MTX
121 ( ) 6T/3X C 20-40ml mg/kg GOT/GPT CK Y Y CK ALP NASH ANA/ /
122 122 3 NSAIDs 2 5 IgM-HA / PT * *28 NASH *29 / *27 *28 / *29
123 B PT / *30 HDF FFP 40 / PT 50% PT HDF ( p.202) kcal/kg *30 D/T /
124 % * % 2-5g/kg/ 15-30% * g/kg/ 0.6g/kg/ TPN TPN 1 * kcal/kg/ g/kg/ /N Na meq/ K 20 60meq/ 1g= ( ) 6.25g cal/n N3 4g/ K cal/n N5 7g/ K cal/n kcal/kg/ g/kg/ BCAA * % g/kg/ 20% 40% 40% CO kg * kcal/ *32 3g/kg/ *33 TPN PN *34
125 kcal/kg/ 1500Kcal kcal kcal 4.5g = 28.1g 0.56g 0.7g/kg/ F 350ml 50ml 400ml 1800kcal 50%glu 1000ml kcal/1450ml 5%glu250ml 1800ml 60ml/h 1 / / 2.0g 6. F 400ml 50%glu 1000ml 5%glu 250ml 10%NaCl 20ml MVI TPN TPN 4 ( p.145) TPN 10 /L *35 TPN *35
126 126 3 ICU NG P-ring * cm cm 10ml Xp *36
127 127 4 / 4.1 Na FENa Y Y Na<20mEq/L FENa<1 Y 1g/ / / Y RPGN SLE ANA/ANCA Na / / 30mEq/dl 300mOsm/Kg
128 128 4 / FENa Na FENa = U Na/P Na U Cr /P Cr *1 / 1/ ml * mg * kcal/kg/ * ml/h
129 NSAIDs ACE 2 *3 ACE GFR CRE ACE *4 CRE CRE>1.2mg/dl or CCr <50 ml/min 65 1ml/kg/hr 12 N- *5 600mg NSAIDs CRE *3 *4 *5
130 130 4 / / COX-2 NSAIDs *6 P.80 CK LDH GOT CK ml/h *7 ( P.204) CK N- *8 CRE 5 *9 *6 COX-2 *7 3-4L/ *8 600mg 12 *9
131 4.2 BUN/CRE 131 K ( / / ) 4.2 BUN/CRE ANCA GBM Y / Y ASO/ASK Y ANCA GBM / C-ANCA P-ANCA GBM Wegener Chrug- Strauss TTP/HUS Good pasture GBM Y IgA
132 132 4 / Y 24 3g/ Y Bence Jones β2 NSAIDs mg 300mg/ 3
133 g 4.4 Y PT/APTT/ Y Y 1g/ CT/IVP DIC Y / Y ANCA / /
134 134 4 / 4.5 K K BUN/CRE / Y = 10% 5-10ml 3 K 50% 50ml+ 10U K 5 20ml 5 1-2A Y K K Y ph,glu,ck,ua K 200mEq/day Y 2ng/dl Y - NSAIDs ACE 21- Hydroxylase K K mmol/l K 6.5mmol/l 10% 10ml 15
135 4.6 K % 50ml 10 β GI 10-20mg K 2mmol/ 1 GI K g K K K K K 10mEq/h 20-40mEq/h K 10mEq K 0.1mEq/l K
136 136 4 / K Y Y Na Na Y K Y K 20mEq/day K Y / -Y Cl 10mEq/day 10mEq/day Mg 40mEq/l 60mEq/l 1 Cl *10 ( p.20) *10 Cl
137 4.7 Na 137 K (25mg)1-2T/1X 3-6T/3X 4.7 Na Na / Y Y / 0.7 Na Na 10mEq/dl Na Y Na 20mEq/dl Na/ ( Na ) 1/2 5% 5% 2(Na + + K + ) + ( glu 18 ) + ( BUN ) 2.8
138 138 4 / (mosm/kg) mOsm Na 1. ( ) Na = 0.6 (kg) % mEq/L 4. 1/2
139 4.8 Na Na Na Na ( mOsm) = Y Na Na BUN/CRE BUN/ SIADH Na SIADH Na 36% SIADH 28% 14% 4.7% 1.6% Na SIADH 16% 6.3% 1.6% 4.2 Na
140 140 4 / Na Na 1. 1L Na Na 3% 513mEq/l 154mEq/l 4. Na 1L Na + = Na+ Na + (L) Na 10mEq/l 6. 70kg Na 120mEq/l 130mEq/l a 1L Na 154(mEq/l) 120(mEq/l) 70(kg) = 0.79mEq/l b 3 Na 130mEq/l 1 3mEq/l c 1 4L *11 d 2000ml Na Na SIADH / SIADH Na U-Osm>150 P-Osm<280 Na>20meq/dl ADH *11 3%
141 4.9 Ca mg 2 3% 1-2ml/kg/h 3 Na 1-2meq/h 3% a 400ml/h Na 100meq/L b Na 40meq/h 3% 78ml/h c 1 350ml Na 1% d 4 / Na ml/ 5 Na Ca Ca P ipth 1.25(OH)VitD CBC CBC Y P ipth Y Ca Y / / Ca PTHrP Y Vit.D Vit.D
142 142 4 / 54% 35% 9.2% 1.0% 0.5% VitD 0.5% 4.3 Ca Ca % Ca Ca Ca Ca Ca = Ca(mg/dl) (4.0 alb(g/dl)) Ca 14mg/dl / 100ml/h *12 90mg 1 60mg 2 * mg
143 4.10 Ca Ca Ca Y Y 4g/dl Ca = Ca (4.0 alb) N PTH Y D P Mg Ca 4.11 / K K P T QRS ( )
144 144 4 / / 4 5% K 6 a CPAP b a 3-5ml/h b 5cmH2O
145 /3 1/
146 ( ) R R N (21 ) N /3 1/3 2 2 : 7:3 *1 3 5:5 *2 4 I I 5% 1000ml KCl 20meq ml/h 1-3 /h *1 30R N R *2 50R 30R
147 Y 3 Step1; mg/dl Y Step2; mg/dl Y Step3; mg/dl Y Step4; mg/dl II II 1000ml 5% 20meq KCl ml/h
148 % DKA 4 BUN CRE 300 Na DKA AMY DKA 6-8L ml ml/h 300 1/
149 U/kg/h * U/h 4. DKA HCO 3 HCO 3 * DKA K mEq K 5.2 KCl P K KCl (meq KCl/L) > < KCl 2 6 K R 50 50ml (1ml=1 ) *3 *4
150 ml/h ml/h ml/h ml/h ml/h ml/h ml/h ml/h 5.3 R 10 IVH 600mg/dl 340 mosm/l Na ml ml/h 1/ U/h
151 / / /Ca/CK/ / Y Y Y NSAIDs BUN/CRE Na/ /SHADH CK /chol /DKA Ca GOT/GPT TP /alb p.196
152 TSH Y Y N Y TSH N (PTU) (MMI) PTU T 4 T 3 PTU MMI CBC TSH T 4 T 3
153 PTU mg NG MMI 1 30mg 8 *5 250mg * mg 6 100mg 6 *7 β 1mg/min 2-4 PSL 30mg/ 2 CRP 5.4 *5 *6 1 1ml * mg
154 154 5 ACTH : 1. ACTH 250µg Y Y ACTH 18µg/dl ACTH = ACTH Y CT MRI Na K 200mg mg ACTH
155 ACTH
156 CBC/ Y Y / MCV :80-100fl MCV MCV MCV Coombs bil VitB12 LDH VitB12 TIBC Hb Hb
157 / % 15-36% B12/ % MDS/ 5.6% / 2.8% 17% TIBC Y Y Y TIBC / TIBC TIBC VitB6
158 mg/ VitB12 Y VitB12 VitB12 VitB12 Coombs MDS
159 VitB12 VitB12 100ng/ml 7 VitB12 100µg 1 VitB12 150ng/ml VitB12 1mg/ IgG LDH 1mg/kg MAP
160 160 6 CBC Y Y DIC Coombs HUS/TTP / (bil/ldh ) Coombs PT/APTT Y N G6PD PNH MAP 1 Hb mg FFP 1 80ml FFP 10 32g *1 Na mEq/dl K 3.3mEq/dl *1 1 12g/
161 ml( 10ml) ml /PT/APTT/FDP / / Y APTT/PT APTT PT Y FDP VIII Y TTP ITP von Willebrand DIC K ITP
162 162 6 PT APTT Y PT/APTT DIC ITP Y DIC C S - SLE ITP SLE DIC/TTP (PAIgG) 2-3 1mg/kg g/kg 5 4 1
163 TTP LDH LDH1000 TTP FFP 60-80ml/kg/ mg/kg / HIT *2 1 INR
164 164 6 APTT/PT APTT/PT APTT PT VIII Y FDP DIC K K FFP K FFP FOY/ AT-III K1-2mg 4.5 FFP 2.0 K2.5-10mg FFP 6.2 INR 4-5 INR INR 5-9 K 1-2.5mg K *2 6A/
165 INR K 5mg K INR 9 (2.5-5mg) K 24 INR INR K FFP 15ml/kg *3 DIC DIC PT FDP ( 1000/µl) PT( )(PT ) (mg/dl) FDP (µg/ml) :1 DIC 7 DIC 6.3 DIC 5-15U/Kg/hr ATIII 50% ATIII /kg 1 1 FOY 1-2mg/kg/hr mg/kg/hr 24 FOY 100mg/dl (FFP) 1 4 *3 4-5
166 mg/kg 8 DIC / SLE / AT-III ACT APTT APTT APTT ACT ACT ACT APTT APTT
167 * U/kg ( 5000 ) 2. 14U/kg/h * APTT APTT 2 2 APTT U/kg/h U/kg/h U/kg/h U/kg/h U/kg/h ml 100ml 6ml/h( ) P.163 3% 5 15 *4 ACT *5 50kg
168 PT PT 65 / 2.5-5mg/1X PT / 5-7.5mg/1X 2 PT INR < mg mg mg >2.5 0mg INR <1.5 5mg mg mg >2.5 0mg Day INR 1-2 / PT 3 < mg mg mg INR mg < % >3 0mg % 4 < mg % mg % mg VitK > mg 1-2mg 24 INR 5 < mg 10.0 P mg mg > mg 6 < mg mg mg > mg
169 O2 Y Y Y / CT BUN/CRE / PaO2 or PaCO2 CO2 50% VitB1
170 170 7 hypoxia-ischemia 42% 30% 15% 13% 10% 7.6% 3.8% 3.2% 2.4% * / CPR a a *1
171 % 40ml / 5l CBC/ / / 50%glu 2A Vit.B1 100mg 50%glu a a 50%glu
172 172 7 CT CT / PCR HSV-PCR COPD / p.182
173 p ml p.150 p.202 P % % 40ml 100mg a a
174 174 7 / Y 50%glu 1A / Na Ca Mg Y Y Y / 12 CT Y N N CAG/
175 A a a 1A a / Na K Ca Mg a /
176 176 7 a b 250mg/1A+ 100ml 50mg/ c a 2 b c 2A 1A a b 5A+ 40ml 2ml/h c a b c 10ml/h
177 CT / / CT / CT 1A PCR HSV- PCR ICU ICU 7.2.2
178 178 7 *2 CT Ca Mg K *3 * ml/h *2 / / *3 *4
179 Y Y Y / Y CT CT 0.4mg/kg 2g 7.3.1
180 180 7 CT / / a a CT CT 0.5g / *5 *5
181 / NSAIDs *6 / / 400mg 1A *7 β / / CT *8 1 *6 3T/3X *7 1 *8 CT
182 % 7.5% (Jolt Accentuation) CT PCR *9 / 2 / Y Y / Y / 2/3 Y CT Y φ3cm CT *9
183 *10 2g 2g mg/kg 2 MRSA *11 10mg/kg *12 CT 3T/3X *13 ESR *10 ABPC *11 *12 *13
184 mg/ / % Y MRI
185 a CT MRI a
186 186 7 CT a / / a CT 18 CT 3 CT APTT CT
187 7.5 / 187 B1 B1 100mg/ MRI 8 30mg/kg * mg/kg/h / Y Y Y N Y TIA MRI MRI *14 50kg 1500mg
188 188 7 aphasia dysarthria 7.6 /CK/ESR Y Y / N / MRI CIDP N / ALS Y Y Ca/Mg/P / / Y CK Y SLE
189 /mm 3 *15 0.4g/kg 5 SpO2 BiPAP 3-4 ALS COPD CT *16 Ach *15 *16
190 T/3X 1A mg/ 7.7 / Y / / / / / Y MRI MRI Dix-HallPike Epley Y / AS/MS
191 7.7 / / *17 *18 100mg/2X 200mg/2X *17 *18
192 192 7 L-Dopa *19 / Dix-HallPike BPPV Epley 7.1 Dix-HallPike / 3 CT 1A * 20 1A 30 Epley *19 2 *20
193 Epley A B Dix-Hallpike B C C D 90 D E E 7.8 Y Y Y Y TIA N
194 P * mg/dl (7.5mg/dl ) NSAIDs NSAIDs *21
195 Y Y / Y / Y WBC 5000 NSAID WBC SLE DNA / / 85% SLE ANA SLE ANA 95% DNA LE
196 196 7 / / 15% ( 40mm ) CRP 30mg 10 NSAIDs P.112
197 Y Y Y CIDP VitB12 MRI & B12 CIDP
198 mg/ 0.5-1mg/ p.188 Fogaty 7.11 / / / Y Y CT Y Y / Ca SLE Pick / / Y MRI
199 / SpO2 Y Y Y Y CT CT 2 Y / / / / 50% / / / β NSAIDs H2
200 mg ( ) 1mg
201 201 8 / NG 1 1g
202 202 8 / 1mEq/kg *1 1L / / g 140mg/kg 70mg/kg % 100% 10ml 30ml *1 2A
203 % 10ml/kg ml/kg/h / / / BAL2.5mg/kg mg mg mg 1mg HbCO 5% 10% 7.5% Xp
204 204 8 / 84% 78% / 53% 44% 2.9% % *2 100% mEq/kg * mEq 1000ml 1/ ml/h 3. QRS 0.1msec *2 *3 2
205 ( ) (1A=0.5mg=1ml) A 3mm (1A=500mg=20ml) 2-4A 2-4A 2-4A ml/h 8.2 ( ) ( )
206 206 8 / CRP / BAL *4 2g/1X + 400mg/2X 3g/3X+ 400mg/2X *5 4T/2X *4 *5
207 A * mg/kg 7 16 (1-4 ). 3 20% 5 :HI EIA(IgG) HI IgM *
208 208 8 / 3 EB EBNA IgG-VCA EBNA VCA-IgG VCA-IgG + + EBNA EB 10 4
209 / 11. / /PCR / N
210 210 8 / Y Y Y Xp Y Xp / 3 Y * ( ) Xp 20mm *7 5
211 mm *8 INH 7 8 mg/kg 6 3 Y Xp/CT Y Y 50mm / Y Y SLE N ACE MRI IL2 Still EBNA IgG-VCA ANCA CF *8 29
212 212 8 / 8.3 HBs HBs HCV HIV HBs HBs HCV HIV HBs HBs HCV HIV HBs (+) HCV (+) HIV (+) Y HBs HBs HIV (16 ) HB 1/2/3/6 HCV 2 48 AZT 200mg 3TC HBIG 150mg mg 1/3/5/6 1/2/3/6 (HBs HBs HCV HIV ) GOT GPT LDH ALP γ-gtp T-bil HBV HBs HBe / ( ) HBV HBV 3-37% HBV
213 HBIG( HBs ) 48 HBV HBs HBe HBe HBV HBV HBV HBc 210 HBV HBs (+) 2 10 HBV ( ) 8.3 B HBV HBs HBe 22-31% B 37-62% HBs HBe 1-6% HB 23-37% B B (HBIG: ) HBV ( ) HBIG 1 1 HBs HBV HBs HBs HBe HBIG 85-95% HBIG 70-75% HB 1 HBIG 75% HBIG
214 214 8 / HB B HBIG HCV HBV / HCV 3-10% HCV HCV 1-2% HCV HCV 1.8% HCV 1994 ACIP HCV FDA HCV HCV GOT
215 HIV HIV DNA HCV HCV HCV GOT ) 2)GOT GPT 3) HCV HIV HIV (90% ) ZDV HIV 79% HIV zidovudine (ZDV) lamivudine (3TC) indinavir (IDV) STS (+) TPHA (+)
216 216 8 / RPR(rapid plasma reagin card test) TPHA(Treponema pallidum hemaglutination test) RPR RPR TPHA RPR(+)TPHA(-) (SLE ) RPR 2-3 RPR 4 TPHA TP RPR STS 6 2 TP RPR STS RPR RPR (8-16 ) ( RPR 8-16 ) 10
217 217 A-aDO2, 21 ACLS, 93 ACT, 166 ALS, 189 ARDS, 43 ATN, 128 Burugada, 66 Churg-Strauss, 5, 10 COPD, 20 COPD, 21 DIC, 165 Dix-Hallpike, 192 Epley, 193 FENa, 128 FFP, 160 Guillain-Barre, 188 B, 212 C, 214 HIT, 163 HIV, 215 ITP, 161 Mallory-Weiss, 99 MAP, 160 MMI, 152 Mobitz2, 65 NASH, 122 PBC, 120 PTU, 152 QT, 65 SBP, 115 SIADH, 140 SLE, 195 TTP, 163 Wegener, 44, 153, 159, 32, 202, 202, 71, 10, 51, 25, 72, 113, 26, 176, 10, 169, 201, 203, 50, 149, 145, 146, 183, 186, 124, 26, 112, 119, 130
218 218, 106, 117, 57, 85, 85, 201, 58, 45, 134, 84, 134, 40, 141, 119, 142, 114, 83, 44, 84, 16, 145, 121, 152, 194, 187, 49, 152, 82, 74, 152, 31, 150, 9, 37, 8, 37, 35, 38, 15, 59, 137, 75, 164, 33, 166, 35, 11, 118, 20, 51, 209, 122, 109, 161, 164, 201, 27, 45, 27, 204, 53, 12, 53, 43, 105, 29, 131, 111, 159, 188, 188, 61, 44, 61, 181, 193, 135, 197, 134, 81, 189, 174, 92, 123, 161, 111, 100, 20, 113, 29, 49, 210, 157, 162, 177, 161, 194, 137, 69, 31, 71, 133, 76
219 219, 126, 135, 108, 143, 100, 139, 39, 158, 88, 157, 47, 208, 56, 24, 89, 43, 70, 75, 130, 85, 17, 148, 127, 65, 86, 22, 50, 97, 26, 50, 89, 18, 176, 72, 59, 140, 107, 116, 207, 24, 182, 197, 179, 25, 145, 202, 137, 159, 110, 187, 127, 151, 110, 9, 9, 5, 80, 129, 64, 183, 72, 158, 24, 64, 188, 120, 107, 132, 72, 198, 62, 108, 109, 87, 194, 28, 186, 181, 205, 50, 191, 136, 77, 205, 209, 19, 16, 58, 215, 46 =, 34, 73, 156, 212, 213, 79
220 220, 203, 176, 156, 70, 61, 64, 202, 207, 190, 199, 205, 153, 113, 128, 101, 121, 103, 201, 183, 105, 80, 160, 211, 72, 79, 158, 167, 159, 166, 166, 106, 71, 180, 30, 203, 195, 116, 196, 116, 196, 192, 65, 184, 84, 206, 184, 117, 117, 27, 164, 71
CharacterSets.book Japanese
FRAMEMAKER 9 ADOBE i................................................. 2 1 2 1 2 3 4 ú þ ý! " # $ % & ( ) * +, -. / 0 1 2 3 4 5 5 6 7 8 9 : ; < = >? @ A B C D E F G H I J K L M N O P Q R S T U 6 V W X
2 5 * * *2 *2 7 'm arhi Szmiya from ast jnior high irst off 'm not interested in ordinary peope t if any of yo are aiens timetraveers or espers pease ome see me That is a i * * * *irosoft ffie 9 *5 *
ph
14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................
CPR 20 4 3 3 1 5 1.1................... 5 1.1.1....................... 5 1.1.2.................. 5 1.2........................ 7 1.3 =...................... 7 2 11 2.1..................... 11 2.2........................
csj-report.pdf
23 2 *1 CSJ 3302 661 CSJ 2.1 2.2 CSJ 2.6 2.7 XML XML 8 2.1 1 CSJ CSJ CSJ 661 4 50 *1 24 2 2.1.1 CSJ 2.1.2 2.1.1 CSJ CSJ 0.2 0.2 3302 20 CSJ 5 3 0.2 0.05 2.1 25 2.2 CSJ FEP 2.3 CSJ 1.7.2 2004a 2002 26 2
1) a) b) CRP c) d) e) a,b b,c c,d d,e a,e b,d 2) CKD a) ACE ARB b) 2mg/dL ACE ARB c) 2mg/dL d) e) ACE ARB a,b b,c c,d d,e a,e b,d 3) a) 130/85mmHg b)
2010.1.13 1) 4) 2 18 1) 1 2 3 4 2) 1 2 85 3 3) 1 metabolizer 2 metabolizer 3 metabolizer 4 metabolizer 4) CYP 1 2 metabolizer 3 metabolizer 4 5 6 4 7 2 5 (PPI) 1 2 PPI 2 3 2 3 3 3 3 PPI 3 1 ph 4 5 1) 5)
日本呼吸器学会雑誌第48巻第6号
Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium
21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty
高脂血症の検査
35 30 Buffy coatbuffy coat EDTA Na Na Ca RBC Hb Ht WBC Plt ESR TP Alb CRP GOTGPTLDH BUN Cre UA HbA1C TC TG NaKClCaPFe B12 36 RBC 410530 /μl 380480 /μl Hb 13.517.6g/dL 11.315.2g/dL Ht 3648% 3443% MCV MCH
生化学検査 臨床検査基準値一覧 近畿大学病院 (1) 検査項目 基準値 単位 検査項目 基準値 単位 CRP mg/dl WBC /μl Na mmol/l M RBC K mmol/l F 3.86-
生化学検査 近畿大学病院 (1) CRP 0.00-0.14 WBC 3.3-8.6 10 3 /μl Na 138-145 mmol/l M 4.35-5.55 RBC K 3.6-4.8 mmol/l F 3.86-4.92 10 6 /μl Cl 101-108 mmol/l M 13.7-16.8 HGB g/dl Ca 8.8-10.1 F 11.6-14.8 Pi 2.7-4.6 液 M
DMC-SZ3
DMC-SZ3 & http://panasonic.jp/support/dsc/ VQT4S06-1 F1212KD1023 & & & & È AF > = 1 2 3 ( 4 8 9 5 6 7 10 11 12 1: 3 2: 4 3: 2 4: 1 3421 4 4 13 14 15 16 17 18 19 20 21 22 1 2 1 1 3 1 2 & 1 2 3 1
Microsoft Word - 平成24年度医学部卒業試験問題-2.docx
24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)
ブロック体A
0 1 2 3 4 5 6 7 8 9 a b c d e f g h i j k l m n o p q r s t u v w x y z A B C D E F G H I J K L M N O P Q R S T U W X Y Z! $ % & ( ) *, -. / ; : < >? [ ] ` å Å ß Æ Ø æ ø ƒ Œ œ fi fl ı ˆ ˇ Â Î Ô ª º 0 1
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
Ÿ š ( š ) 300,000,000 14. 3.22 116,500,963 40,185,547 76,315,416 81,749,456 76,275,801 965,801 63,510,000 11,800,000 39,615 39,615 3,227,059 3,227,059
š ( š ) Ÿœ f 240,000 240,000 130,000 240,000 100,000 240,000 110,000 500,000 240,000 3 240,000 500,000 240,000 240,000 500,000 240,000 500,000 100,000 200,000 200,000 90,000 4,106,000 500,000 14. 4. 1
(1) ) ) (2) (3) (4) (5) (1) (2) b (3)..
... -1... -1... -2... -6.... -1 (1)... -1 1)... -1 2)... -14 (2)... -19 (3)... -52 (4)... -18 (5)... -136.... -196 (1)... -196 (2) b... -224 (3)... -233.... -251.... -286.... -289 (1)... -289 (2)... -32
1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2
15 1 12 1 2 2 2 2.1.............................. 3 2.2........................... 3 2.3 β........................ 6 2.4............................ 7 3 8 3.1....................... 8 3.2....................
128号新
155 662-0834 10-22 0798-67-4691 FAX 0798-63-4044 Email koudou@gamma.ocn.ne.jp http://koudou.jp/ 01170-3-4901 _ ³ Ü A Ü ½ Ä ª Á Ä «Ü µ ½ B - ú µ Ì ÅŠ é A â ½ Æ ÌŒb Ý ðš Ó ½ µ Ü B @ @ µ µ A ŠE Ì l X
¾ Ã
½ ½ ½ ½½ ½ ½¼ ½ ¼¼¼ ¼¼¼ ¼¼¼ ¼¼¼ ¼¼¼ ¼¼¼ ¾ ½ Æ ¾ ½ ½½ ½ ½ ¾¼ ½ ¼¼ ½¼ ½ ¾ ¾¹ ¹ ¹ ÌÌ ¾ Ã ¾ ½ ½ ½ ¼ ½ ¼¼ ½¼ ½ ¼ ¾¼ ½¾ ½ ¾¼ ¾¼ ½ Ä ÐÓÒ Ð ÖÒ Ò Ä ÐÓÒ Ù Ø ÓÒ ½ ¼ ÍÒ Ú Ö ØÝ ÓÙÒ Ð ½ ¾ ½ ½ ¾ ½ ½ ½ ½ ½¾ ½ ½ ¾ ¼ ¼
( š ) 4,000,000 i 200,000,000 300,000 1,697,600,000 14.12.17 3,316.63fl 306,200,000 14.12.17 656.46fl 201,000,000 14.12.17 991.92fl 33,300,000 14.12.1
( š ) ( ) J lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll ¾ 15 16. 3.30 24,991,213,640 7,582,598,663 17,408,614,977 17,387,622,157 (434,864) 1,304,592,530 204,300,000 4,000,000 200,300,000
125 2 P 1st washout 2 PB P mg/dL nd washout 2 P 5.5mg/dL< mg/dL <2.5mg/dL P P 2 D D 3 Ca 10
. (1) 125 1 125 Renagel PB-94 P intact-pth P 1 b c a b 1 18 2 3 3 3 1 P 4 D 1 5 6 7 2 1HIV 2 3 4 5Hb 8.0g/dL ALT 48IU/L 6 7 PB-94 440mg 403mg 1-196 125 2 P 1st washout 2 PB-94 1 2 4 4 P 2.5 5.5mg/dL 1
( ) œ 18,120,000 18,000,000 j 120,000 150,000 303,122,619 1,697,600,000 14.12.17 3,316.63fl 306,200,000 14.12.17 656.46fl 201,000,000 14.12.17 991.92f
( ) ( ) œ J lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll ¾ 14 15. 3.28 21,412,684,359 6,028,609,527 15,384,074,832 13,830,085,696 (367,937) 1,103,812,000 321,392,619 18,000,000 270,000
DMC-TZ57
DMC-TZ57 & http://panasonic.jp/support/dsc/ SQW0168-1 F0215MR1025 & ### & ### ### ### & & È È AF > = 1 2 3 4 5 ( 1: 3È 2: 4# 3: 2ë 4: 1 6 7 8 9 10 11 1213 14 3421 4 4 ### 15 16 17 18 19 20 21 22 2324
R E-DO
2005 ... 6... 7... 7... 7... 8... 8... 8... 9... 9...10...10...10...10...11...11...17...19... 20...20...20...20 R E-DO...21...21...21...22...22...22...23...23... 24 2 ICU...24...24...24...24...25...26...26...26...27...27...27
FinePix F460 使用説明書
1 4 5 6 BL00504-101(1) e 007 006 004 00 005 0 0 1 1 1. AM A M NP-40N 4 N 1 5 6 1 B B e d * fi p û ü» Å w B Ò Ú p Ç Â Â Û B r 4 ã é ê 5 6 p w ë î Î ï ó 1 4 5 6 7 e y y y y y y y y y 8 x x x x x p x x NP-40N
WBC 5700 / l Gran 58.5% Lym 29.0% Eosin 0.3% RBC 499x10 6 / l Hb 14.8 g/dl Hct 44.40% PLT 15.3x10 3 / l PT 157% Fbg 616 mg/dl DD 0.99 g/ml GOT GPT LDH
54 2002 3 1992 2002 3 2002 7 2004 1 15 4Kg74.0Kg 1 24 80.6 kg BUN 26.0mg/dl, s-cr 2.3mg/dl, 3+ 1 27 40 /34 174.3 cm 80.6 kg 1 10kg36.8 120/70 mmhg 88 / 14 / fibrinogen 616 mg/dl, TP 3.6 g/dl, Alb 1.4 g/dl,
untitled
š ( ) œ I 100,000 100,000 100,000 100,000 100,000 100,000 I f 100,000 100,000 100,000 100,000 100,000 100,000 2,000,000 110,000 I 70,000 800,210 4,642,500 (1) 2,366,860 22.11.16 24. 3.15 0 0 24. 5.28 23,351,338
J. JAPANESE ASSOC. PETROL. TECHNOL. Vol. 62, No. 2 (1997)
JOURNAL OF THE JAPANESE ASSOCIATION FOR PETROLEUM TECHNOLOGY VOL. 62, NO. 2 (March, 1997) (Received January, 22, 1997; accepted March 26, 1997) Niigata-Sendai natural gas pipeline project Takashi Egawa
( š ) Ÿ 4,086,376 76,423 3,702,178 307,775 165,305 7,075 800,000 150,000 397,000 300,000 3,342,945 16. 3.31 42,745,006 727,728 42,017,278 41,879,733 4
Ÿ ( š ) 60,000 60,000 500,000 100,000 120,000 60,000 120,000 60,000 120,000 120,000 120,000 120,000 120,000 1,200,000 240,000 60,000 60,000 120,000 60,000 120,000 60,000 600,000 1,120,000 60,000 120,000
九州支部卒後研修会症例
血液検査研修会 ( 第 25 回 ) 検査の異常から探る! 造血器腫瘍へのアプローチ 症例提示 症例 1~8 - 症例発表者 - 症例 1 藤崎恵熊本医療センター 症例 2 荒木敏造浜の町病院 症例 3 古城剛鹿児島大学病院 症例 4 佐々木高太郎都城健康サービスセンター 症例 5 矢田佳愛 大分県立病院 症例 6 下田博臣 健康保険諫早総合病院 症例 7 堤陽子 佐賀県医療センター好生館 症例 8
untitled
Ÿ ( œ ) œ 26. 2.13 21,369,678 4,385,959 16,983,719 21,369,678 3,919,030 3,919,030 13,000,000 13,000,000 64,689 64,689 16,137,568 8,199,890 2,655 3,347,109 4,587,914 5,232,110 213,000 1,524,230 2,475,631
untitled
( œ ) ( ) œ J lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll ¾ 24 25. 3.28 19,183,616,151 5,411,950,717 13,771,665,434 13,616,096,406 (449,383) 1,285,202,000 205,070,000 40,000 5,030,000
š ( š ) Ÿ 1,681,268 100,000 16,519,700 (826) 1,661,677 17. 3.31 55,613,224 865,273 54,747,951 55,613,224 2,568,266 2,568,266 52,179,685 52,179,685 33,
Ÿ š ( š ) 400,000 60,000 60,000 1,000,000 100,000 120,000 60,000 120,000 60,000 120,000 120,000 120,000 120,000 120,000 120,000 1,200,000 240,000 60,000 60,000 120,000 60,000 120,000 60,000 600,000 120,000
untitled
Metabolic syndrome,,,, 81 81 , 17 17 2 Lung Ca non small cell carcinoma / / food( food( ) drug( drug( ) 100mg 750mg WBC 5510/ l RBC 483 / l Hb 10.3g/dl, Ht 42.0% Plt 19.0 / l TP 8.1g/dl Alb 4.6g/dl Glb
日本呼吸器学会雑誌第44巻第10号
β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG
untitled
š š ( œ ) 1,000 23. 3.16 105,041,779 81,238,942 23,802,837 60,287,753 23,802,084 7,692,084 6,310,000 9,800,000 753 753 4,195,443 2,864,813 166,352 1,164,278 56,092,310 1,182,200 105,650 105,650 4,460 50,000,000
2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,
24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998
レジデント初期研修用資料 内科診療ヒントブック 改訂2版
2 E-mail kaihatu@ohmsha.co.jp FAX 03-3293-2825 p.13 p.22 p.27 p.31 p.36 p.44 p.50 p.72 p.88 p.95 p.102 p.110 p.123 p.138 p.142 p.150 p.155 p.160 p.163 p.170 p.168 p.175 p.182 p.188 p.198 p.208 p.219 K
慈大呼吸器_25-1_02T_CS5.indd
ISSN 0919-6870. Jikei Journal of Chest Diseases Jikei University Chest Diseases Research Association 82 1 1 1 1 1 1 1 1 2 1 2 74 2010 2 2011 8 12 2012 1 17 1 20 1 28 CT 5 / 50 2011 8 2 / 1200 mg/2x 40
/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 3 2 5/ :90 / :114/64 mmhg
17 2005/12/28 UP 3+, TP 4.2g/dl, Alb 1.9g/dl PSL 50mg/day 1/17 PSL 45mg/day PSL 2006/4/4 PSL 30mg/day mpsl mpsl1000mg 32 5/8 36.1 :90 /:114/64 mmhg 166.2 cm64.3 kg 3.9 g/dl 1.6 g/dl 382 mg/dl 408 mg/dl
総研大「大学共同利用機関の歴史とアーカイブズ」プロジェクト全体会（2008年度）
ß ½º ½ ¼ ½ ÁÁ ½ ¾ ½ ½ ½ ¼ ¾ ½ ½ ¾ ¾º ½ ½¼ ¾¼¼ ¼¼ ½ ÁÁ º ½ ¼¼ ½ ½ ½ ¾º ½¾ ½ ½ Ñ ½¼ ½ ÁÁ ½ ½ ¼ ½¼ ½ ½ ÁÁ ¾¼¼ ½½ ½½ ½ ½¾ ½½ ½¾ ½½ ¾¼¼ º ¹½½ ½ ½¾ ¾¼¼ º½¼ ½ ¾ º º½º ½ ½ ¼¼ ¾¼¼ Ñ ½ ¾ ½ ½¼¼ È ÐÓ ÓÔ Ð ÌÖ Ò Ø ÓÒ
SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P
11 a. 2012 1 15 26 http://www1.koalanet.ne.jp/anesth_memorandum/sub19.html SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO2 20 30 8 10mL/kg I/E CPAP PEEP 27 b. CO2 ( ) SpO2 COPD PETCO2
Ÿ ( ) 360,000 700,000 240,000 480,000 320,000 220,000 20. 6. 6 0 0 52,649,855 20. 3.28 92,262,557 15,709,106 76,553,451 85,612,669 (24) 1,250,000 75,3
( ) g 60,000 120,000 1,200,000 120,000 100,000 60,000 60,000 120,000 721,052 60,000 10,000,000 120,000 120,000 120,000 90,000 60,000 600,000 146,396,863 2,000,000 2,500,000 1,000,000 200,000 10,000,000
1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE 2 Ach ChE PAM ChE
1 - d- etc etc d-tc ChE > < < < > > > or 1.1 1 d- < dtc Na + Na + I II ChE ChE ChE ( ) T Ca++ 1 Na + K + Na + Ach Ach Ach BTX Mg 2+ Ach CAT TTX Ach 1.2 M N M d- BBB / ChE etc ChE etc CCh BCh etc Ach ChE
untitled
1 ... 3... 3... 3... 4...13...16...18...20...22 2 PTPE 3 PTPE CT Grade 2 A PTPE PTPE 4 A S 3 3 B H3,P1,N1,M1, LM0, R23 15 20gS, ptype 3, 60 x 50mm, pt4b/siurinary bladder, int, INF, ly2, v1, ppm070mm,
untitled
œ š ( ) 6,300,736 341,040 341,040 71,400 58 21. 3.25 15,270,513 371,620 14,898,893 14,280,080 (524) 582,000 4,266,000 4,266,000 10,000,000 10,000,000 50,893 50,893 6,569,868 1,463,157 130,532 1,557,951
日本呼吸器学会雑誌第44巻第1号
β β l β β Table1 Laboratorydataonadmission Hematology WBC 9,910/μl neut 72.4% lym 20.2% eos 0.9% mon 6.1% baso 0.4% RBC 491 10 4 /μl Hb 16.8g/dl Ht 48.3% PLT 29.8 10 4 /μl ESR 3mm/hr Biochemistry TP Alb
官報（号外第196号）
( ) š 60,000 13. 2. 8 39,305,000 39,305,000 39,305,000 39,305,000 31,750,000 7,555,000 39,305,000 39,305,000 1,000,000 1,000,000 1,000,000 500,000 500,000 1,000,000 1,000,000 1,000,000 1,000,000 500,000
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
マニュアル第４版表紙PDF
5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.
untitled
ÎÓк ½ ÆÓº ¾ ¾¼¼ ¼ ß ½ ÆÈÇ ½ ÆÈÇ ½ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ½ ÆÈÇ ÆÈÇ ÆÈÇ ¾ ÆÈÇ ÆÈÇ ¾ ¾ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ½ ¼½¹¼½ ¾ ¹Å Ð Ø Ò Ñ ØÙÑÛº Û ¹Ñº º Ô ¼ ¼ ÆÈÇ ½ ½ ½ ½ ¾ ½ ½ ¾ ½ ½ ÆÈÇ ¼ ÆÈÇ ÆÈÇ ÆÈÇ ÆÈÇ ¾ ½ ¾ ¾
1 2 2 ANCA pouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - ' UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, cm 61
1 2 2 ANCApouci immune IgG C3 ANCA 68 '01 '02 7 UN 14mg/dl, Cr 0.7 mg/dl, -, - '03 2 3 31 UN 45mg/dl, Cr 2.4 mg/dl, Ht 29.5%, 4+, 3+ 4 14 156.0 cm 61.5 kg 36.9 158/92 mmhg 90 1. ANCA 2. 3. IgG4 deposit
may-fest.dvi
½ ¾½ ¾¼¼½ ¾¼¼½ ¾ ¾ Á ½ ½ ½º½ ½º¾ ½º ¾ Ž ¾º½ ¾º½º½ ¾º½º¾ ¾º½º ¾º¾ ½¼ ¾º¾º½ ½¼ ¾º¾º¾ ½¼ ¾º¾º ½¼ ¾º¾º ½½ ¾º¾º ½½ ¾º¾º ½½ ¾º¾º ½¾ ¾º¾º ½¾ ¾º¾º ½¾ ¾º¾º½¼» ½¾ ¾º¾º½½ ½ ¾º ½ ž ½ ¾½ º½ ¾½ º¾ ¾½ º ¾¾ º ¾¾ º
国試過去問集.PDF
I 89 16 3 130 ab c AMPcAMP a 1 --- b c --- 2 --- --- 3 --- --- 4 --- --- 5 --- --- camp camp Ca 2+ β1 camp A camp camp A β1 p.156 β p.146 b. p.157 p135 (ANP) p157 c PDE-III p.157 p.157, 183 PDE C Ca PDE-III
untitled
½ Ź ÖÝ ËÃ È Ö ÓÖÑ Ò Ó Å¹ ÖÝ ËÃ Û Ø À ÓÑÔ Ø ÓÒ Ö ÕÙ ÒݹËÐÓØ ÖÖ Ò Ñ ÒØ ½¼ ¼ ½¼ ¾¼¼ ¾ ¾ Ź ÖÝ Ëà Ź ÖÝ ËÃ Ö ÕÙ Òݹ Ø Ý Ò µ º º Å ÐÓ ¾ Å Ø º Ź Ëà Ź ËûÀ Å À ÓÑÔ Ø ÓÒ ÅÓ ÙÐ Ø ÓÒµ º Ź Ëà Ź Ëà º ʵ º Ź
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
GL_高野班_D.indd
Circulation Journal Vol. 72, Suppl. IV, 2008 1443 PCI CCU STEMI CABG ST ST1 EBM ST ST ST ST ST ST 1 EBMEvidence-Based Medicine 1444 Circulation Journal Vol. 72, Suppl. IV, 2008 ACS ST T ST CLBBB ST ACS
untitled
¾¼½¼ ß À ÐØ Ý Ä ËÙÔÔÓÖØ ÓÖ Ð ÖÐÝ Ä Ú Ò Ò Ð ËØ ÖÓÑ ÆÙÖ Ò È Ö Ô Ø Ú ½ Ã Ó Ì Ã ½ ½¼¼ ½µ ¾µ ½ ¼½¹¼½ ¾ ¹Å Ð Ø ÑÛº Û ¹Ñº º Ô ¾ ¾ ½ ½ ½ ¾ ¼ ¼ ¾¼ ¾ ½ ¾ µ ½ ½ µ ½ Ô½ ½º¾ ¾ ¾ ½ ½ ¼ µ µ ½ ½ µ ½ ¾ ½ µ µ ¾ µ ½ ¼ ¾
ê ê ê ê 2
ê ê ê ê 2 242637 178 50 1,300 87-2807 3 @A 4 19 21 19 20 200 5 21 ë ê 31 22 1218 26 20 17 100,000 1,000,000 30,000 10,000 10,000 21 4 2 5 3 4 4 5 20 6 13 7 ê ë 8 @ 19302130 19002100 13301530 19002000 9
š ( ) šœ 190,000 190,000 190,000 185,254,000 152,619,670 152,619,670 32,634,330 32,634,330 190,000 34,204,595 15,747,511 832,718 572,379 17,051,987 11
š š ( ) 39,668 24,958,628,315 4,528,393,902 1,392,762,565 3,184,250,793 91,739 2,736,997,413 17. 3.30 185,064,000 152,429,670 152,429,670 32,634,330 32,634,330 16. 4.20 57,622,500 16. 7.20 57,622,500 16.10.20
新郷村ホームページ
ò ò ò ò ò ò ò ò 022012 ò ò ò I½ ½ ò ò ò ò ò ò ò ò ò ò ò 022021 http://www.city.hirosaki.aomori.jp/ ò ò ò I½ ½ ò ò ò ò ò ò ò ò ò ò ò 022039 http://www.city.hachinohe.aomori.jp ò ò ò I½ ½ ò ò ò ò ò ò
jps03.dvi
¾ ØØÔ»» ÜºÔ Ý ºØÓ Ó Ùº º Ô ½ ¾º½ ½ ½µ ¾µ µ µ ½ ¾ ½¼¼ µ ѵ ¾ ¾ Ñ ¾ Ñ ½Ñ ½Ñ ½Ñ ½ÒÑ ½¼ ½Ñµ ¾º¾ ½ÑÑ ½ Ñ ½ÒÑ ¾ ØØÔ»»ÓÒØ ØºØ Ò Õ٠غ Öº Ô»ØÕ ¾¼¼½» ¼»ØÓÔº ØÑ ¾¼¼ µ µ µ ¾ ¾º ¾º º½ µ µ µ ¾¼¼ ¾º º¾ ½ÒÑ ½¼ ½Ñµ ½
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) ( 10 2 %) (g/l) ( 10 2 %) 0.75 ( 10 2 %) 0.15 ( 10 2 %)
/ B B ( ) ( -298) VL VH( ) Very Low( ) Very High( ) (10 2 %) 0.32 0.55 0.37 0.55 95 165 115 185 (10 2 %) 0.75 (10 2 %) 0.15 (10 2 %) 0.10 10 2 % 0.10 10 2 % 0.15 10 2 % 0.10 Bands(10 2 %) 0.10 (10 9 75
2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.
2 章 +αの 情 報 に 着 目 する! 1 血 球 算 定 検 査 結 果 2 生 化 学 検 査 結 果 手 がかりに 乏 しいのも+α 1 症 例 をみてみよう! 1 60 吉 見 祐 輔 1 2 11percutaneous coronary intervention PCI104 38.1 130 75mmHg 83 16 SpO 297 1 3 WBCL RBC10 4 L Hb g
Sample2 g/dl Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl
( ) Sample2 g/dl 10 9 8 7 6 Target1 : 6.01 g/dl TP Target2 : 8.39 g/dl 117 5.92 0.09 1.6 118 5.92 0.10 1.6 7 5.77 0.14 2.4 118 8.28 0.15 1.8 118 8.28 0.15 1.8 7 7.26 0.46 6.4 119 119 6.84 7.10 0.11 0.11
( ) š 19. 1.11 19. 1.24 19. 2. 5 19. 3.19 19. 6.20 19. 3.23 606,151 606,114 37 115,167 37 37 115,167 114,390 777 19. 4. 5 19. 4. 2 19. 2.21 19. 3. 1 2
šÿ ( ) 120,000 1,000,000 60,000 108,000 1,000,000 120,000 120,000 60,000 240,000 390,000 908,000 56,380,000 ø 19. 2. 8 34,008,466 2,952,753 31,055,713 21,636,246 3,394,000 3,036,000 358,000 27,661,409
mg 8 mg X Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD
31 1 15 20 2016 15 3 65 5 mg 8 mg 10 15 201X 7 1 11 15 Cr 9.84 mg/ dl K 1.5 meq/l CK 24,570 U/L Mb 79,530 ng/ml Mb 230,000 ng/ ml AKI 2 IHD IHD 4 IHD AKI HD 2004 48 Acute Kidney Injury AKI 48 Cr 0.3 mg/dl
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
1 0 [ : trn] ( 6 7 (overview.pdf (segment.pdf 1 1 ID ID % ID: %<SOT> %<EOT> ( A B ( C A B ( D ( A ( ( 1 ID= B D
![1 0 [ : trn] ( 6 7 (overview.pdf (segment.pdf 1 1 ID ID % ID: %<SOT> %<EOT> ( A B ( C A B ( D ( A ( ( 1 ID= B D](/thumbs/43/23128119.jpg "1 0 [ : trn] ( 6 7 (overview.pdf (segment.pdf 1 1 ID ID % ID: %<SOT> %<EOT> ( A B ( C A B ( D ( A ( ( 1 ID= B D")
Version 1.0,, 0 1 1 1 2 3 3 4 3.1....................................... 4 3.2............................ 5 3.3................................. 6 3.4..................................... 6 3.5......................................
<8C9F8DB85F3338E4508CB495612E786C73>
尿 検 査 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり 随 時 尿 蛋 白 ( 定 性 ) - - - 糖 ( 定 性 ) - - - 潜 血 ( 定 性 ) - - - 項 目 に が 付 与 されている 場 合 : 該 当 の 項 目 は 1/5 尿 検 査 血 球 算 定 初 回 登 録 前 回 調 査 時 から 変 更 なし 追 加 データあり WBC ( )
日本医師会雑誌第131巻第10号
B C 100 12 11 13 3 C 4 C Q&A B C 54 B B B B Q&A B B HBV 20 HBV B B B B HBV HBV HBV HBV 2 HBV HBV HBV A HBV HBV HBV HBV HBV Q37 HBV HBV HBV 1015 B B B Q51 B HBV B B HBV B HBV HBV HBV B B B HBV B HBV HBV
š ( ) ,987,270,000 2,550,000,000 3,367,410,490 2,304,024,754 1,063,385, ,385,736 2,170,000, ,580, ,58
¾ š ( ) ( ) lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll J N R L š ( ) 16 17. 3.30 2,987,270,000 2,550,000,000 3,367,410,490 2,304,024,754 1,063,385,736 683,385,736 2,170,000,000 16.
基準値一覧 ( 平成 24 年 6 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科
基準値一覧 ( 平成 24 年 6 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科 項目名 検査法 単位 基準値 M F TP ビュレット法 g/dl 6.3~8.2 ALB BCG 法 g/dl 3.5~5.2 A/G 演算 1.26~2.26 ZTT 硫酸亜鉛混濁 KU 4.0~12.0 TBIL 酵素法 mg/dl 0.30~1.20 DBIL 酵素法 mg/dl 0.00~0.30
<8C9F8DB889C88AEE8F80926C88EA A E342E312E786C73>
基準値一覧 ( 平成 27 年 4 月 1 日 ) 独立行政法人国立病院機構東京医療センター 臨床検査科 項目名 検査法 単位 基準値 M F TP ビュレット法 g/dl 6.3~8.2 ALB BCG 法 g/dl 3.5~5.2 A/G 演算 1.26~2.26 ZTT 硫酸亜鉛混濁 KU 4.0~12.0 TBIL 酵素法 mg/dl 0.30~1.20 DBIL 酵素法 mg/dl 0.00~0.30
š ( š ) œš 1,179,203 1,179,203 566,201 116,791 237,560 211,850 613,002 438,985 150,497 150,497 23,520 500,000 679,203 17. 3.18 17. 3.11 17. 3.30 17. 1
œ š ( š ) 3,525,422 384,000 60,000 60,000 60,000 60,000 60,000 150,000 100,000 60,000 60,000 100,000 60,000 1,500,000 240,000 120,000 60,000 300,000 60,000 420,000 1,000,000 18,430,000 (460) j 1,500,000
Ł\”ƒ1-4
1 2 (1) 4 (2) 4 (3) 5 (4) 7 (5) 7 (1) 8 (2) 11 (3) 12 (4) 13 (5) 14 (6) 19 (1) 20 (2) 22 (3) 24 (4) 10 27 (5) 28 (1) 34 (2) 39 (3) 42 (4) 45 (1) 52 (2) 66 (3) 67 (4) 69 (1) 71 (2) 71 (3) 72 (4) 72 (5)
72 20 Ope / class Alb g/ cm 47.9kg : /min 112/60m
72 20Ope 68 69 2006 4 50 20 / 52 2006 4 1 2006 4 4 24 class 699.4 5 2 5 23 6 6 15 6 19 6 16 Alb2.03+ 7.5g/ 6 21 153.5cm 47.9kg : 36.7 89/min112/60mmHg (-) (-)S1 S2 S3(-) S4(-) - - 6 15 (+) TP4.9g/dl Alb2.0g/
血糖高いのは朝食後のため検査項目 下限値上限値 単位名称 9 月 3 日 9 月 6 日 9 月 15 日 9 月 18 日 9 月 21 日 9 月 24 日 9 月 28 日 10 月 1 日 10 月 3 日 10 月 5 日 10 月 9 日 10 月 12 日 10 月 15 日 10 月
検査項目 下限値上限値 単位名称 7 月 9 日 7 月 10 日 7 月 11 日 7 月 12 日 7 月 13 日 7 月 17 日 7 月 20 日 7 月 23 日 7 月 25 日 7 月 27 日 7 月 30 日 8 月 3 日 8 月 6 日 8 月 8 日 8 月 10 日 8 月 12 日 8 月 15 日 8 月 17 日 8 月 20 日 8 月 22 日 8 月 24 日
1996 papilloma virus 2001 Bowen AIHA PSL1mg/kg BMA PRCA parvovirus B19 PVB19 DNA PCR PV IgM 4 PVB19 PRCA MAP PVB19 DNA DNA PR
1996 papilloma virus 2001 Bowen2002 12 2003 2 2002 9 10 AIHA PSL1mg/kg BMAPRCA parvovirus B19 PVB19 DNA PCR PV IgM 4PVB19 PRCA MAPPVB19DNA DNA PRCA IVIG;20 50g/ IVIG PVB19AIHA steroid 15 20mg/day 2003
A(6, 13) B(1, 1) 65 y C 2 A(2, 1) B( 3, 2) C 66 x + 2y 1 = 0 2 A(1, 1) B(3, 0) P 67 3 A(3, 3) B(1, 2) C(4, 0) (1) ABC G (2) 3 A B C P 6
1 1 1.1 64 A6, 1) B1, 1) 65 C A, 1) B, ) C 66 + 1 = 0 A1, 1) B, 0) P 67 A, ) B1, ) C4, 0) 1) ABC G ) A B C P 64 A 1, 1) B, ) AB AB = 1) + 1) A 1, 1) 1 B, ) 1 65 66 65 C0, k) 66 1 p, p) 1 1 A B AB A 67
¾ ¾¼½ ¾ º½ ¾ ÖÜ Ì Ü Ä Ù Å Ù Ü Ì Æ Þµ Þµ Þ ÞµÈ Ç ½ ¾ Ü Ì Ü Ì Þµ Ù Ö Ü Þ Ì Æ Þµ Þµ ÙÅ ÔÐÒØ Ü Ä Ü Ì Ç º½ ¾
Title 転 がり 案 内 を 有 する 位 置 決 め 機 構 に 対 する 摩 擦 モデリン グと 補 償 Author(s) 前 田, 佳 弘 Citation Issue Date 211-3-16 URL http://repo.lib.nitech.ac.jp/handle Rights Type Thesis or Dissertation Textversion author 名
Gifu University Hospital Cancer Center 1 2 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center 3 4 Gifu University Hospital Cancer Center Gifu University Hospital Cancer Center
untitled
Ref. No: KiG14B23-Kokushi22-R01 22 1/23 Ans Ans 1 75 64 74 8 75 75 Ans 9 75.1 2010 Ans Ans 1000 Ans 85cm 90cm 25 130mmHg 85mmHg 100mg/dl HbA1c 5.6 HDL 150mg/dl HDL-C 40mg/dl 1 3 Ans 1 (): 2 (): 3 (): 4
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5
Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl
untitled
28 20 1 31 4 2 25 1 IgG IgA IgM IgE IgM 2 60 80 70 60 60 40 20 80 35 45 kg 150cc 100 120cc 100cc 30 40cc 7,000g 500cc 120cc 120 5=600cc 600g 30 2,100cc 1,000cc 3 4 14 5 6 7 8 9 10 11 12 SIDS SIDS SIDS
( )
18 10 01 ( ) 1 2018 4 1.1 2018............................... 4 1.2 2018......................... 5 2 2017 7 2.1 2017............................... 7 2.2 2017......................... 8 3 2016 9 3.1 2016...............................
ron0223.dvi
Ï Ú ÐÓÔÑ ÒØ Ó Ø Ð ÓÖ ØÓÖÝ ÕÙ ÔÑ ÒØ ÓÖ Û Ö Ð ØÝ ¼ ½¾¼¼½¼ ½ À ÖÓ Ë Ø ¾¼¼ ½ ½ ¾ ½º½ ¾ ½º¾ ½º¾º½ ½º¾º¾ ½¼ ½º¾º ½¾ ½º ½ ¾ ½ ¾º½ ÀÌÅÄ ½ ¾º¾ ËË ½ ¾º ½ ¾º º½ ËË ½ ¾º º¾ ËË ½ ¾º º ½ ¾º º ½ ¾º º ½ ¾ º½ ¾ º¾ ËË ¾
š œ ( š ) 10 11 12 13 6364 œ
š œ ( š ) Å š œ ( š ) 10 11 12 13 6364 œ š œ ( š ) 270 135 72 10 85250480 200365695 230345 200365 695 50 60 71 23205 200 35 65190420 135260590 180250 135260590 50 101112 52 70 200 AcHbAc12 13 TdT1415 100100500
METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,
2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002
B 温泉用語集v2 ABC順090617.xls
é é é üü é ßä ö ß ä é é é ß ö é é ü üö ä é é é é é ä é ä ä éé ä ä ä ä é é éé é Ü é ü é à ä ä ü ö ß ä é â é éé é ß ä ä éé é ö é é ä é é é éé éè éé ä é ü ßß ö œ ß üß à éé é éé é éé é ü ö é ää ä ßßä éé ä
<8C9F8DB889C890B38FED926C88EA E31302E31816A81602E786C73>
一覧 ( 平成 22 年 10 月 1 日 ) 独立行政法人国立病院機構 東京医療センター 臨床検査科臨床検査技師長 奥田勲 項目名 夜間休日対応 至急対応 検査法 単位 M F TP ビュレット法 g/dl 6.3~8.2 ALB BCG 法 g/dl 3.5~5.2 A/G 演算 1.26~2.26 ZTT 硫酸亜鉛混濁 KU 4.0~12.0 TBIL 酵素法 mg/dl 0.30~1.20
日本呼吸器学会雑誌第44巻第6号
Aspergillus β Table1 Laboratoryfindingsonadmission Hematology WB Seg Band Lymph Eos Baso RB Hb Hct Plt Biochemistry AST ALT LD ALP γ-gtp K 17,700 /mm 3 70.0 % 7.0 % 17.0 % 2.0 % 1.0 % 337 10 4 /mm 3 11.5g/dl
cjnl22
'05/07/30 Vol. 33 CONTACT Japan - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - - 10 - - 11 - - 12 - - 13 - - 14 - - 15 - W Ò WŒã L Ã æ ± Ç d qƒ [ƒ ˆ Ä æ ID contactj@tty.gr.jp ƒ [ƒšƒ ƒoƒšƒxƒg o ^
untitled
ÎÓк ½ ÆÓº ½ ¾¼¼ ß ½ ½ ¾ ¾¾¾ ½ ¼½ ¾½ ½º ± º ± ½ º ± ¾ ¾½º ±½½¼ º½± Ï ÐÐ¹Ò È Ò ½ ¾ ½ ÏÀÇ ÏÓÖÐ À ÖØ ÇÖ Ò Þ Ø ÓÒ ½µ ¾¼¼ ¾µ ݽµ ¾¼¼ ݾµ µ ½ ¼ ½ ¼ ½ ¼ µ ½ ¾ ¼½¹¼½ ½ ¹Å Ð ÓÝ Ù º Û ¹Ñº º Ô ¼ µ µ µ ÏÀÇÉÇÄ ËÊÈ
59 20 : 50 : : : : : 2 / :20 / 25 GTP /28 5/3 5/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3 :78 / :156/78mmHg 1
59 20 : 50 : 2005 9 : 2006 1 : 2006 4 : :2 / :20 / 25 GTP 2006 1 4/28 5/35/4 5/8 6/1 1 7kg 6/9 :178.7cm :68.55kg BMI:21.47 :37.3:78 / :156/78mmHg 1 0.3g 1 30-49 Hb9.5g/dL 7 /mm 3 - Cr1.6mg/dL CRP1.84 mg/dl
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5